A new study found that infants receiving maternal Respiratory Syncytial Virus (RSV) vaccination or Nirsevimab after birth had significantly lower RSV infection and health care use compared to unprotected infants. It also showed fewer severe complications in RSV-positive infants with prevention. These findings highlight the positive impact of RSV preventive measures in high-risk populations. Findings from the study will be presented at the Pediatric Academic Societies (PAS) 2026 Meeting, taking place April 24–27 in Boston.
This article was originally published on MedicalXpress.com
